Clinical Trials Logo

Clinical Trial Summary

Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance the clinical impact of cognitive remediation and other rehabilitative interventions for Veterans living with chronic psychosis, this study will develop novel brain-based tools to help identify those Veterans who are most likely to benefit from pro-cognitive therapies. These studies may advance predictive algorithms that improve functional outcomes and life quality in Veterans with schizophrenia.


Clinical Trial Description

This is an observational study recruiting Veterans with a diagnosis of Schizophrenia (SZ) and other Chronic Psychotic Disorders and Veterans in good general health (HS) who are enrolled in and/or receiving care at the VA San Diego Healthcare System. Eighty Veterans will undergo comprehensive neurophysiological, clinical, cognitive, and functional assessments in two "phases" (Phase 1: 30 SZ, 20 HS; Phase 2: 30 SZ). In Phase 1 (Biomarker Optimization; Aims 1 & 2), Veterans will undergo systematic neurophysiologic testing designed to elicit spectral biomarkers linked to cortical excitation and inhibition ("E/I balance") during passive and stimulated conditions on two separate test visits (1-2 weeks apart). Experimental conditions will then be optimized for internal consistency and test-retest reliability using Generalizability Theory. The optimized biomarkers will be carried forward into Phase 2 (Biomarker Validation; Aim 3), where these neurophysiologic measures will be assessed before and after Veterans with SZ undergo 1 hour of cognitive training as a demonstration of neural system target engagement. This proposal has 3 specific aims: Aim 1. Identify the experimental conditions that optimize the psychometric properties (i.e., sensitivity to detect individual differences) of the spectral biomarkers linked to E/I balance. Aim 2. Characterize the relationships of spectral biomarkers with rehabilitation-relevant outcomes. Aim 3. Evaluate the sensitivity of the optimized E/I measures in predicting performance during an acute, 1-hour exposure to computerized cognitive training. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05945602
Study type Observational
Source VA Office of Research and Development
Contact Juan Molina, MD
Phone (202) 555-8975
Email Juan.Molina@va.gov
Status Recruiting
Phase
Start date October 1, 2023
Completion date September 30, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT06136390 - OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia N/A
Active, not recruiting NCT04230590 - Health Outcomes Via Positive Engagement in Schizophrenia
Recruiting NCT05333003 - Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity N/A
Withdrawn NCT03883360 - Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Phase 2
Completed NCT04799717 - Game-based Telehealth Therapeutic Intervention in First Onset Psychosis
Completed NCT05247151 - The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin N/A
Completed NCT05784948 - Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis N/A
Recruiting NCT06138054 - MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI N/A
Completed NCT02283437 - A Problem-solving Based Bibliotherapy Program for Family Caregivers in Schizophrenia N/A